Generic Times Product News

Claravis (isotretinoin capsules USP, 30 mg)

Marketed by: Barr Laboratories Inc, a subsidiary of Barr Pharmaceuticals Inc (Woodcliff Lake, NJ)

Compared to: Claravis capsules 30 mg will compete with Ranbaxy's Sotret (isotretinoin) Capsules USP 30 mg.

Indication: May 12, 2006—Barr Laboratories received FDA approval to manufacture and market isotretinoin capsules, 30 mg, under the trade name Claravis. With the approval for this strength, the company will now market the full line of isotretinoin product strengths. Claravis is indicated for the treatment of severe recalcitrant nodular acne.

Dosage Form: Capsules: 10, 20, 30, and 40 mg

For More Information: www.barrlabs.com

Metronidazole Lotion 0.75%

Marketed by: Fougera, a division of ALTANA Inc (Melville, NY)

Compared to: MetroLotion (Galderma)

Indication: May 24, 2006—Fougera announced that it was first to market with metronidazole lotion 0.75%. It was approved by the FDA and is indicated for the treatment of rosacea. The lotion is available in a 59-mL bottle.

Dosage Form: Lotion: 59-mL bottle

For More Information: www.fougera.com 800-645-9833

Polyethylene Glycol 3350, NF Powder for Oral Solution

Marketed by: Paddock Laboratories Inc (Minneapolis, Minn)

Compared to: MiraLax (Braintree Laboratories Inc)

Indication: May 2006—Paddock Laboratories announced the introduction of Polyethylene Glycol 3350, NF Powder for Oral Solution. It is an osmotic agent that causes water to be retained with the stool and is indicated for the treatment of occasional constipation.

Dosage Form: 255-and 527-g bottles

For More Information: www.paddocklabs.com 800-328-5113

Probenecid Tablets 500 mg, USP

Marketed by: Lannett Co Inc (Philadelphia, Pa)

Compared to: Benemid Tablets (Merck & Co Inc)

Indication: May 22, 2006—Lannett Co Inc received FDA approval for probenecid tablets 500 mg, USP. The product is indicated for the treatment of hyperuricemia associated with gout and gouty arthritis. It is also used as adjunctive therapy with some antibiotics such as penicillin, ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given.

Dosage Form: Tablets: 500 mg

For More Information: www.lannett.com

Urea 35% Lotion

Marketed by: Glades Pharmaceuticals, LLC, a wholly owned subsidiary of Stiefel Laboratories (Duluth, Ga)

Compared to: Keralac Lotion (Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals Inc)

Indication: May 15, 2006—Glades Pharmaceuticals announced the addition of Urea 35% Lotion, with the same active ingredient as Keralac Lotion, to its efficacious line of urea-based keratolytic agents. This new addition will join the company's line of Urea 40% Cream, Gel, and Lotion products. It is an effective treatment option for hyperkeratotic conditions, including dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns, and calluses.

Dosage Form: Lotion: 207-and 325-mL bottles

For More Information: www.glades.com